tiprankstipranks
Atea Pharmaceuticals (AVIR)
NASDAQ:AVIR
US Market
Holding AVIR?
Track your performance easily

Atea Pharmaceuticals (AVIR) Ownership - Who Owns Atea Pharmaceuticals?

209 Followers

Atea Pharmaceuticals (AVIR) Ownership Overview

11.90%14.39%27.46%11.35%34.91%
11.90% Insiders
27.46% Other Institutional Investors
11.35% ETFs
34.91% Public Companies and
Individual Investors
The ownership structure of Atea Pharmaceuticals (AVIR) stock is a mix of institutional, retail, and individual investors. Approximately 53.20% of the company’s stock is owned by Institutional Investors, 11.90% is owned by Insiders, and 34.91% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Jun 21, 2024
Bruce Polsky
Director
xxxxxxxxxxxxx
$61053
Jun 07, 2024
Jean Pierre Sommadossi
President, Ceo, And Chairman,director
xxxxxxxxxxxxx
$4024

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Sep 30, 2024
xxxxxxxxxxxxx
$346249

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
8,162,914Insider9.60%27,509,020
4,250,660Institution5.03%14,324,724
3,785,235Institution4.48%12,756,242
3,576,266Institution4.23%12,052,016
1,811,377Institution2.14%6,104,340
958,300Institution1.13%3,229,471
876,763Institution1.04%2,954,691
869,276Institution1.03%2,929,460
811,867Institution0.96%2,735,992
811,503Insider0.96%2,734,765

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
3,576,266Institution4.23%12,052,016
1,811,377Institution2.14%6,104,340
958,300Institution1.13%3,229,471
876,763Institution1.04%2,954,691
869,276Institution1.03%2,929,460
811,867Institution0.96%2,735,992
549,380Institution0.65%1,851,411
502,608Institution0.60%1,693,789
376,458Institution0.45%1,268,663
342,681Institution0.41%1,154,835

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
2,363,327Institution2.80%7,657,179
2,086,017Institution2.47%6,779,555
1,266,597Institution1.50%4,103,774
746,181Institution0.88%2,425,088
508,111Institution0.60%1,651,361
381,413Institution0.45%1,205,265
352,505Institution0.42%1,142,116
210,100Institution0.25%680,724
176,143Institution0.21%572,465
170,730Institution0.20%554,873

FAQ

Who Owns Atea Pharmaceuticals (AVIR)?
According to the latest TipRanks data, approximately 27.46% of the company's stock is held by institutional investors, 11.90% is held by insiders, and 34.91% is held by retail investors.
    What percentage of Atea Pharmaceuticals (AVIR) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 27.46% of Atea Pharmaceuticals (AVIR) stock is held by institutional investors.
      What percentage of Atea Pharmaceuticals (AVIR) stock is held by retail investors?
      According to the latest TipRanks data, approximately 34.91% of Atea Pharmaceuticals (AVIR) stock is held by retail investors.
        Who owns the most shares of Atea Pharmaceuticals (AVIR)?
        Jean-Pierre Sommadossi owns the most shares of Atea Pharmaceuticals (AVIR).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis